| A homogeneous assay for analysis of FMR1 promoter methylation in patients with fragile X syndrome. | |
| | |
MedLine Citation:
|
PMID: 17259243 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Fragile X syndrome is caused by the expansion of a CGG trinucleotide repeat at the 5' untranslated region of the fragile X mental retardation 1 gene (FMR1). When expanded to >200 repeats (full mutation), the repeat region and the adjacent promoter CpG island become hypermethylated, rendering FMR1 transcriptionally inactive. Conventional molecular diagnosis of fragile X syndrome involves determination of the CGG repeat number by Southern blot analysis. METHODS: A homogeneous methylation-specific melting curve analysis (MS-MCA) assay for methylation status of the FMR1 promoter region was developed on the LightCycler platform. Genomic DNA was treated with sodium bisulfite, and a region containing 8 CpG sites was amplified in the presence of SYBR Green I, using primers that do not differentiate between methylated and unmethylated FMR1 molecules. After amplification, the samples were melted at 0.05 degrees C/s, and fluorescence melting curves were recorded. We studied samples, previously characterized by Southern blot analyses, from 10 female and 10 male donors with normal numbers of CGG trinucleotide repeats, 9 male donors who were premutation carriers, 4 male donors who carried both a premutation and a full mutation, and 25 patients with fragile X syndrome. RESULTS: Samples from all 20 male patients with fragile X syndrome showed a high melting peak corresponding to fully methylated FMR1, whereas samples from healthy males showed a single low melting peak corresponding to unmethylated FMR1. Of 24 samples from affected males, 9 (38%) showed 2 melting peaks, suggesting that cellular methylation mosaicism is common in fragile X syndrome. CONCLUSIONS: MS-MCA allows rapid and reliable identification of fragile X syndrome in male patients. |
| | |
Authors:
|
Christina Dahl; Karen Grønskov; Lars A Larsen; Per Guldberg; Karen Brøndum-Nielsen |
Related Documents
:
|
17618523 - Fragile x-associated tremor/ataxia syndrome: clinical features, genetics, and testing g... 6711593 - An anthropometric study of males with the fragile-x syndrome. 20613953 - Superior vena cava syndrome in a patient with polycytemia vera: diagnosis and treatment. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-01-26 |
Journal Detail:
|
Title: Clinical chemistry Volume: 53 ISSN: 0009-9147 ISO Abbreviation: Clin. Chem. Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-04-04 Completed Date: 2007-05-21 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 9421549 Medline TA: Clin Chem Country: United States |
Other Details:
|
Languages: eng Pagination: 790-3 Citation Subset: IM |
Affiliation:
|
Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
DNA Methylation Female Fragile X Mental Retardation Protein / genetics* Fragile X Syndrome / genetics* Humans Male Polymerase Chain Reaction Promoter Regions, Genetic |
| Chemical | |
Reg. No./Substance:
|
0/FMR1 protein, human; 139135-51-6/Fragile X Mental Retardation Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of the risk for Tay-Sachs disease in individuals of French Canadian ancestry living in ne...
Next Document: Hypothermia during laparotomy can be prevented by locally applied warm water and pulsating negative ...